Science at Pure Biologics

At Pure Biologics, we regularly publish and present our scientific achievements in scientific journals and monographs, as well as at conferences and symposia around the world.

We consider this a perfect test of our ideas and a great means for the scientific community and experts from various fields to evaluate our results. This is also a means of continuous development at the highest level and according to the best scientific standards worldwide.

Papers

Integrin Alpha v Beta 6 and Its Implication in Cancer Treatment
October 15
2022

Integrin Alpha v Beta 6 and Its Implication in Cancer Treatment

Brzozowska E., Deshmukh S.
"International Journal of Molecular Sciences" (2022)
pH-responsive antibodies for therapeutic applications
January 22
2021

pH-responsive antibodies for therapeutic applications

Klaus T., Deshmukh S.
"Journal of Biomedical Science" (2021)
Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company
June 5
2020

Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company

Deshmukh S., Jurek P., Jelen F., Tabaczar S., Bakowski T., Carter D., Fox R., Wawrzyniak M., Mazurek MP.
"Technology Transfer and Entrepreneurship" (2020)
In Chemico Modification of Nucleotides for Better Recognition
October 1
2018

In Chemico Modification of Nucleotides for Better Recognition

Jurek P., Matusiewicz M., Mazurek M., Jelen F.
Y. Dong (red.) "Aptamers for Analytical Applications" (2018)

Posters

Generation of chemically modified aptamers to capture human C5 complement component in myasthenia gravis treatment
April 5
2022

Generation of chemically modified aptamers to capture human C5 complement component in myasthenia gravis treatment

Guzdek J., Majewska J., Piskorz M., Velez Pires F., Dobosz P., Carter D., Krzaczek K., Bąkowski T., Sok-Grochowska A.
Aptamers 2022, Oxford, UK
Development of a bispecific antibody for colorectal cancer: Functional activity evaluation via a biophysical cell-based assay and surface plasmon resonance
October 25
2021

Development of a bispecific antibody for colorectal cancer: Functional activity evaluation via a biophysical cell-based assay and surface plasmon resonance

Pires F., Skulski M., Dudek A., Dobosz P., Kołodziejski J., Carter D.
EMBO Practical Course - Biomolecular interaction analysis 2021: From molecules to cells
Chemically-modified aptamers generation to recognize relevant bacterial antigens and antibiotic resistance proteins
April 15
2021

Chemically-modified aptamers generation to recognize relevant bacterial antigens and antibiotic resistance proteins

Czarnecka M., Puchała M., Guzdek J., Radzińska M., Carter D., Darżynkiewicz ZM., Sołtys K., Adamowicz-Skrzypowska A., Ahmadi Y., Barišić I., Sok-Grochowska A.
Aptamers Virtual 2021, Oxford, UK
Aptamer-enabled adsorber device for specific removal of anti-aquaporin-4 antibodies
September 3
2020

Aptamer-enabled adsorber device for specific removal of anti-aquaporin-4 antibodies

Czarnecka M., Puchała M., Guzdek J., Radzińska M., Dąbrowska B., Sok-Grochowska A., Lopko M., Sołtys K., Darżynkiewicz Z., Liputa E., Carter D., Żurek A., Bąkowski T.
Aptamers Virtual 2020, Oxford, UK
Development Of A Fully Human Antibody Against A Key Immune Checkpoint Modulator
November 18
2019

Development Of A Fully Human Antibody Against A Key Immune Checkpoint Modulator

Dudek A., Kasprzyk O., Klaus T., Opalinska M., Swiat M., Kolodziejski J., Blaszczyk R., Dzwigonska M., Sydor P., Kolodziejczyk R., Poznar M., Carter D., Soltys K., Wawrzyniak M., Deshmukh S.
PEGS, Lisbon, Portugal
Discovery Of Antibodies For Immunotherapy Of CRC Using A Proprietary Phage Display Platform
November 18
2019

Discovery Of Antibodies For Immunotherapy Of CRC Using A Proprietary Phage Display Platform

Kasprzyk O., Klaus T., Witkowicz A., Wilgan B., Swiderski L., Zurek A., Dudek A., Berezowski M., Kostyn A., Blazejewska A., Orlowski M., Krzaczek K., Sztyler M., Jakimowicz P., Soltys K., Carter D., Wawrzyniak M., Deshmukh S.
PEGS, Lisbon, Portugal
PureSelect2 - a novel phage display platform for in vitro selection of therapeutic antibody fragments
April 30
2018

PureSelect2 - a novel phage display platform for in vitro selection of therapeutic antibody fragments

Matusiewicz, M., Sok, A., Margas, E., Swiat, M., Zurek, A., Wilgan, B.
PEGS, Boston, USA
Modular platform for modified aptamers – a selection case study
April 11
2018

Modular platform for modified aptamers – a selection case study

Jurek P., Adamowicz A., Sok A., Mazurek M.
Aptamers 2018, Oxford, UK
Modular platform for modified aptamers
June 28
2017

Modular platform for modified aptamers

Jurek P., Adamowicz A., Sok A., Mazurek M.
Aptamers-in-Bordeaux 2017, Bordeaux, France
Phage Display and SELEX brought together – a bivalent aptamer-antibody conjugate for VEGFR specific targeting
March 31
2015

Phage Display and SELEX brought together – a bivalent aptamer-antibody conjugate for VEGFR specific targeting

Jurek, P., Matusiewicz, M., Piksa, M., P. Mazurek, MP., Jakimowicz, P., Jeleń, F.
Aptamers 2015, Oxford, UK

Patents

The method of synthesis and purification of a nucleoside and/or a nucleotide, a modified nucleoside and/or nucleotide, a DNA molecule and an oligonucleotide library comprising said modified nucleoside and/or nucleotide, and the use of said oligonucleotide library

The method of synthesis and purification of a nucleoside and/or a nucleotide, a modified nucleoside and/or nucleotide, a DNA molecule and an oligonucleotide library comprising said modified nucleoside and/or nucleotide, and the use of said oligonucleotide library

Jurek P., Jelen F., Mazurek M., Jakimowicz P.
United States Patent US10450673
European Patent EP3350195
Polish Patent PL239946
Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers